{"id":"https://openalex.org/W2011357127","doi":"https://doi.org/10.1080/10550490701389658","title":"Comparison of Olanzapine to Risperidone in Substance\u2010Abusing Individuals with Schizophrenia","display_name":"Comparison of Olanzapine to Risperidone in Substance\u2010Abusing Individuals with Schizophrenia","alternate_titles":[],"publication_year":2007,"publication_date":"2007-07-08","ids":{"openalex":"https://openalex.org/W2011357127","doi":"https://doi.org/10.1080/10550490701389658","mag":"2011357127","pmid":"https://pubmed.ncbi.nlm.nih.gov/17661193"},"language":"en","primary_location":{"id":"doi:10.1080/10550490701389658","doi":"https://doi.org/10.1080/10550490701389658","is_oa":false,"landing_page_url":"https://doi.org/10.1080/10550490701389658","pdf_url":null,"source":{"id":"https://openalex.org/S134700381","display_name":"American Journal on Addictions","issn_l":"1055-0496","issn":["1055-0496","1521-0391"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The American Journal on Addictions","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2011357127"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050895675","display_name":"Evaristo Akerele","orcid":"https://orcid.org/0000-0001-8581-2507","observed_orcids":["https://orcid.org/0000-0001-8581-2507"]},"institutions":[{"id":"https://openalex.org/I2802987467","display_name":"Harlem Hospital Center","ror":"https://ror.org/00tz4k675","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802987467"]},{"id":"https://openalex.org/I78577930","display_name":"Columbia University","ror":"https://ror.org/00hj8s172","country_code":"US","type":"education","lineage":["https://openalex.org/I78577930"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Evaristo Akerele","raw_affiliation_strings":["Department of Psychiatry, Harlem Hospital, College of Physicians and Surgeons of Columbia University, New York, New York 10037, USA. ea200@columbia.edu","Department of Psychiatry, Harlem Hospital, College of Physicians and Surgeons of Columbia University, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry, Harlem Hospital, College of Physicians and Surgeons of Columbia University, New York, New York 10037, USA. ea200@columbia.edu","institution_ids":["https://openalex.org/I2802987467","https://openalex.org/I78577930"]},{"raw_affiliation_string":"Department of Psychiatry, Harlem Hospital, College of Physicians and Surgeons of Columbia University, New York, New York","institution_ids":["https://openalex.org/I2802987467","https://openalex.org/I78577930"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083379140","display_name":"FRANCES RUDNICK LEVIN","orcid":"https://orcid.org/0000-0003-4209-1329","observed_orcids":["https://orcid.org/0000-0003-4209-1329"]},"institutions":[{"id":"https://openalex.org/I4388891851","display_name":"New York State Psychiatric Institute","ror":"https://ror.org/04aqjf708","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4388891851"]},{"id":"https://openalex.org/I78577930","display_name":"Columbia University","ror":"https://ror.org/00hj8s172","country_code":"US","type":"education","lineage":["https://openalex.org/I78577930"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Frances R. Levin","raw_affiliation_strings":["New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, New York","institution_ids":["https://openalex.org/I4388891851","https://openalex.org/I78577930"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3920,"currency":"USD","value_usd":3920},"apc_paid":null,"fwci":2.3287,"has_fulltext":false,"cited_by_count":71,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.86518745,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"16","issue":"4","first_page":"260","last_page":"268"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9663000106811523,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9663000106811523,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.022199999541044235,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.002899999963119626,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/olanzapine","display_name":"olanzapine","score":1.0},{"id":"https://openalex.org/keywords/risperidone","display_name":"risperidone","score":1.0},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.9520000219345093},{"id":"https://openalex.org/keywords/substance-abuse","display_name":"substance abuse","score":0.6700000166893005},{"id":"https://openalex.org/keywords/cocaine-dependence","display_name":"cocaine dependence","score":0.7900000214576721},{"id":"https://openalex.org/keywords/drug-craving","display_name":"drug craving","score":0.4909999966621399},{"id":"https://openalex.org/keywords/antipsychotic-efficacy","display_name":"antipsychotic efficacy","score":0.6439999938011169},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.5630000233650208},{"id":"https://openalex.org/keywords/urine-drug-testing","display_name":"urine drug testing","score":0.652999997138977}],"concepts":[{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.9566278457641602},{"id":"https://openalex.org/C2780057945","wikidata":"https://www.wikidata.org/wiki/Q412443","display_name":"Risperidone","level":3,"score":0.9443093538284302},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.6165390610694885},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.5702691674232483},{"id":"https://openalex.org/C2779541405","wikidata":"https://www.wikidata.org/wiki/Q498902","display_name":"Craving","level":3,"score":0.5422344207763672},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.4900425672531128},{"id":"https://openalex.org/C2781353949","wikidata":"https://www.wikidata.org/wiki/Q3271533","display_name":"Dopamine antagonist","level":4,"score":0.4578366279602051},{"id":"https://openalex.org/C3018023364","wikidata":"https://www.wikidata.org/wiki/Q425265","display_name":"Significant difference","level":2,"score":0.42289048433303833},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.37526971101760864},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3205097019672394},{"id":"https://openalex.org/C48856860","wikidata":"https://www.wikidata.org/wiki/Q12029","display_name":"Addiction","level":2,"score":0.26262015104293823},{"id":"https://openalex.org/C2780948584","wikidata":"https://www.wikidata.org/wiki/Q251347","display_name":"Haloperidol","level":3,"score":0.08867356181144714},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.057719141244888306}],"mesh":[{"descriptor_ui":"D000077152","descriptor_name":"Olanzapine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003710","descriptor_name":"Demography","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010349","descriptor_name":"Patient Compliance","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015897","descriptor_name":"Comorbidity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017831","descriptor_name":"Diagnosis, Dual (Psychiatry)","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018967","descriptor_name":"Risperidone","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018967","descriptor_name":"Risperidone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019966","descriptor_name":"Substance-Related Disorders","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D019966","descriptor_name":"Substance-Related Disorders","qualifier_ui":"Q000652","qualifier_name":"urine","is_major_topic":false},{"descriptor_ui":"D039721","descriptor_name":"Diagnostic and Statistical Manual of Mental Disorders","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1080/10550490701389658","doi":"https://doi.org/10.1080/10550490701389658","is_oa":false,"landing_page_url":"https://doi.org/10.1080/10550490701389658","pdf_url":null,"source":{"id":"https://openalex.org/S134700381","display_name":"American Journal on Addictions","issn_l":"1055-0496","issn":["1055-0496","1521-0391"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The American Journal on Addictions","raw_type":"journal-article"},{"id":"pmid:17661193","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17661193","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The American journal on addictions","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9922999739646912}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1821408506","display_name":null,"funder_award_id":"K02 00465","funder_id":"https://openalex.org/F4320332505","funder_display_name":"U.S. Public Health Service"},{"id":"https://openalex.org/G8921917545","display_name":null,"funder_award_id":"K12 00366","funder_id":"https://openalex.org/F4320332505","funder_display_name":"U.S. Public Health Service"}],"funders":[{"id":"https://openalex.org/F4320332505","display_name":"U.S. Public Health Service","ror":"https://ror.org/05xf94514"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":62,"referenced_works":["https://openalex.org/W21666720","https://openalex.org/W69345561","https://openalex.org/W97034663","https://openalex.org/W1943544645","https://openalex.org/W1963512293","https://openalex.org/W1965944328","https://openalex.org/W1966795950","https://openalex.org/W1970541082","https://openalex.org/W1970658022","https://openalex.org/W1971165967","https://openalex.org/W1980733422","https://openalex.org/W1983012591","https://openalex.org/W1983133139","https://openalex.org/W1985517071","https://openalex.org/W1994118834","https://openalex.org/W1995916748","https://openalex.org/W2002916128","https://openalex.org/W2003033559","https://openalex.org/W2004252407","https://openalex.org/W2018279494","https://openalex.org/W2023928188","https://openalex.org/W2024374498","https://openalex.org/W2035793096","https://openalex.org/W2046197750","https://openalex.org/W2063248492","https://openalex.org/W2068281665","https://openalex.org/W2073023197","https://openalex.org/W2073066871","https://openalex.org/W2074216683","https://openalex.org/W2075560932","https://openalex.org/W2076841065","https://openalex.org/W2080953708","https://openalex.org/W2082225329","https://openalex.org/W2091525886","https://openalex.org/W2095217951","https://openalex.org/W2100702853","https://openalex.org/W2104758313","https://openalex.org/W2106493693","https://openalex.org/W2108347048","https://openalex.org/W2112635201","https://openalex.org/W2113107587","https://openalex.org/W2113366774","https://openalex.org/W2114781875","https://openalex.org/W2119758521","https://openalex.org/W2122519801","https://openalex.org/W2123037757","https://openalex.org/W2126261598","https://openalex.org/W2140606211","https://openalex.org/W2157877920","https://openalex.org/W2165379748","https://openalex.org/W2242713226","https://openalex.org/W2316932124","https://openalex.org/W2401206973","https://openalex.org/W2403092971","https://openalex.org/W2414949354","https://openalex.org/W2417149712","https://openalex.org/W2427207108","https://openalex.org/W2912016724","https://openalex.org/W3026900340","https://openalex.org/W3090293687","https://openalex.org/W4247496126","https://openalex.org/W4290371117"],"related_works":["https://openalex.org/W2008902227","https://openalex.org/W2018279494","https://openalex.org/W2018679306","https://openalex.org/W1968924708","https://openalex.org/W2283540979","https://openalex.org/W2106493693","https://openalex.org/W1987272850","https://openalex.org/W2051492382","https://openalex.org/W2162942237","https://openalex.org/W2008205908"],"abstract_inverted_index":{"A":[0],"14-week":[1],"double":[2],"blind":[3],"study":[4,23],"compared":[5,68,86],"the":[6,65,73,83,88,98,110,115],"efficacy":[7],"of":[8,25,42,48,100,112,117],"olanzapine":[9,66,89,113],"to":[10,69,87],"risperidone":[11,70,84],"in":[12,18,97,120],"reducing":[13],"marijuana/cocaine":[14],"craving":[15,78],"and":[16,38],"use":[17],"individuals":[19,121],"with":[20,57,122],"schizophrenia.":[21,123],"The":[22,46,104],"consisted":[24],"three":[26],"phases:":[27],"a":[28,32,39,58,61],"two-week":[29,33],"assessment":[30],"phase,":[31],"cross-taper":[34],"phase":[35],"onto":[36],"olanzapine/risperidone,":[37],"ten-week":[40],"period":[41],"maintenance":[43],"on":[44],"olanzapine/risperidone.":[45],"proportion":[47,99],"cocaine-positive":[49],"urines":[50],"decreases":[51],"over":[52],"time":[53],"for":[54,60,64,82,109,114],"both":[55],"groups":[56],"trend":[59],"greater":[62],"reduction":[63],"group":[67,85,95],"group.":[71],"In":[72],"last":[74],"six":[75],"weeks,":[76],"marijuana":[77,102],"was":[79,93],"more":[80],"likely":[81],"group,":[90],"although":[91],"there":[92],"no":[94],"difference":[96],"negative":[101],"urines.":[103],"data":[105],"suggest":[106],"some":[107],"potential":[108],"utility":[111],"treatment":[116],"cocaine":[118],"dependence":[119]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2011357127","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
